PROGNOSTXHEALTH
DEAD

Serial Number

97542778

Owner

AmDx PrognostX, Inc.

Attorney

Monte L. Falcoff

Filing Date

Aug 10, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PROGNOSTXHEALTH Trademark

Serial Number: 97542778

PROGNOSTXHEALTH is a trademark filed by AmDx PrognostX, Inc. on August 10, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

AmDx PrognostX, Inc. (3 trademarks)

6508 Old Floydsburg Road, STE-4, BLDG-2
Pewee Valley, KY 400569116

Entity Type: 03

PROGNOSTX HEALTH INC. (3 trademarks)

6508 OLD FLOYDSBURG ROAD
PEWEE VALLEY, KY 40056-9116

Entity Type: 03

Trademark Details

Filing Date

August 10, 2022

Registration Date

Not Registered

Published for Opposition

November 21, 2023

Goods & Services

Computer hardware, recorded software, and control algorithms sold as a unit for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers including cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder

diagnostic kits and instruments primarily comprised of immunological assays, antibodies and reagents for medical testing of diseases; testing apparatus and instruments being diagnostic kits for medical or research purposes primarily comprised of reagents for creating assays to capture and detect disease biomarkers

Medical diagnostic services relating to diseases; medical testing services relating to the diagnosis and treatment of disease; Medical services, namely, administering reagent-based sample tests for others for diagnosis of diseases; Providing medical diagnostic information services for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers, cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder using computers, software and algorithms

diagnostic kits and instruments primarily comprised of a coated surface, a reagent and an immunoassay using antibodies or molecular probes for medical diagnosis of diseases and medical use; testing apparatus and instruments for medical purposes in the nature of a coated plate or other surface materials including but not limited to plastic, glass, or metals used to create assays to capture and detect disease biomarkers; Medical diagnostic and therapeutic apparatuses primarily comprised of antibody or antigen coated surfaces, reagents, immunoassays, computers, software and algorithms for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers including cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder

Biomedical research services; scientific laboratory services; providing reagent sample testing for others in the fields of medical diseases and medicine; Development of testing for kidney diseases in a laboratory setting; Medical and scientific research, namely, conducting clinical trials for others featuring clinical trial design, statistical evaluation, and execution; Scientific and medical research and consulting services featuring algorithms, artificial intelligence and machine learning development, evaluation and clinical utility; Scientific and medical research and consulting services featuring biostatistical support; Manufacturing services, namely, development of minimal viable products in the nature of medical diagnostic tests for others; consulting services related to laboratory developed testing procedures, strategy and execution in the field of medical diagnostics, medical tests and pharmaceutical research; Quality evaluation of clinical utility and applicability of innovative technologies in the medical field

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 17, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 17, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 3, 2024 EXRA
SOU EXTENSION 1 GRANTED
Oct 3, 2024 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 3, 2024 AITU
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 11, 2024 ASGN
SOU EXTENSION 1 FILED
Jul 9, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 9, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 16, 2024 NOAM
ASSIGNED TO EXAMINER
Dec 5, 2023 DOCK
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 21, 2023 NPUB
PUBLISHED FOR OPPOSITION
Nov 21, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 1, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 13, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 13, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 13, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 13, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 7, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 6, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 6, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 8, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 8, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 8, 2023 CNRT
ASSIGNED TO EXAMINER
May 30, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 30, 2022 NWOS
NEW APPLICATION ENTERED
Aug 13, 2022 NWAP